Centre for Modern Indian Studies, University of Goettingen, Goettingen, Germany.
Heidelberg Institute of Global Health, University of Heidelberg, Heidelberg, Germany.
Am J Clin Nutr. 2020 Nov 11;112(5):1219-1227. doi: 10.1093/ajcn/nqaa196.
Despite ongoing debate about the health impact of probiotics, rigorous evidence assessing the use of probiotics in routine preterm newborn care is lacking.
We aimed to estimate the causal effect of routine probiotics supplementation on moderately preterm newborns' anthropometric development (weight-for-age and height-for-age z scores) and risk of late-onset sepsis.
This study used a regression discontinuity analysis based on hospital guidelines that recommended routine probiotics supplementation for neonates born before 34 completed weeks of gestation. Data for this study came from electronic medical records of a level III neonatal care center in Germany and were collected between 2013 and 2019. Newborns born between 30 to 38 completed weeks of gestation without severe congenital defects were eligible for inclusion. Outcomes were weight-for-age and height-for-age z scores at discharge as well as late-onset sepsis.
Study participants included 1734 preterm neonates. The results showed no significant intention-to-treat effect on weight-for-age (effect: -0.033 SD; 95% CI: -0.220, 0.155), length-for-age (-0.133 SD; 95% CI: -0.380, 0.114), or late-onset sepsis probability (-1.175 percentage points; 95% CI: -6.556, 4.205). There was no evidence for significant effects of probiotics for any of the study's endpoints on those complying with the hospital guidelines (local average treatment effect).
Routine treatment of moderately preterm newborns with probiotics is unlikely to improve anthropometric outcomes. Complier-level analysis suggested that this finding was not simply driven by a lack of physician compliance with hospital guidelines but by an overall absence of large health effects from the treatment itself. Moreover, overall sepsis risk was low and did not change significantly as a result of probiotics supplementation. The findings of this study therefore do not support the routine use of probiotics for improving growth or preventing late-onset sepsis in moderately preterm neonates.
尽管关于益生菌对健康的影响仍存在争议,但缺乏严格评估益生菌在常规早产儿护理中应用的证据。
我们旨在评估常规益生菌补充对中度早产儿生长发育(体重-年龄和身高-年龄 z 评分)和晚发性败血症风险的因果效应。
本研究采用基于医院指南的回归不连续性分析,该指南建议对胎龄 34 周前出生的新生儿常规补充益生菌。本研究的数据来自德国一家三级新生儿护理中心的电子病历,数据收集时间为 2013 年至 2019 年。胎龄 30 至 38 周且无严重先天性缺陷的新生儿符合纳入标准。主要结局为出院时的体重-年龄和身高-年龄 z 评分以及晚发性败血症。
研究纳入了 1734 名早产儿。结果显示,意向治疗对体重-年龄(效应:-0.033 标准差;95%CI:-0.220,0.155)、身长-年龄(-0.133 标准差;95%CI:-0.380,0.114)或晚发性败血症发生率(-1.175 个百分点;95%CI:-6.556,4.205)均无显著影响。对于符合医院指南的患者(局部平均处理效应),益生菌对任何研究终点的治疗效果也均无显著影响。
对中度早产儿常规使用益生菌不太可能改善生长发育结局。基于依从性的分析表明,这一结果并非仅仅是由于医生不遵守医院指南,而是由于治疗本身并未带来显著的总体健康影响。此外,总体败血症风险较低,补充益生菌后并未显著改变。因此,本研究结果不支持常规使用益生菌来改善中度早产儿的生长或预防晚发性败血症。